Company news
AN2 Therapeutics, Inc. news in 2022
AN2 Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 8, 2022
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease
October 5, 2022
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
September 28, 2022
AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 10, 2022
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
June 28, 2022
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 9, 2022
AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
May 8, 2022
AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering
March 23, 2022